HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on SAB Biotherapeutics (NASDAQ:SABS) and maintained a $6 price target on the stock.
April 16, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reaffirmed a Buy rating on SAB Biotherapeutics and maintained a $6 price target.
The reiteration of a Buy rating and maintenance of a $6 price target by a reputable analyst could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100